Diverse biological activities of the vascular non-inflammatory molecules - The Vanin pantetheinases

Biochemical and Biophysical Research Communications

Volumn 417, Issue 2, 2012, Pages 653-658

  Kaskow, Belinda J ^a   Michael Proffit, J ^b   Blangero, John ^b   Moses, Eric K ^a,b   Abraham, Lawrence J ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Cardiovascular disease; Cysteamine; Pantetheinase; Vanin

Indexed keywords

COENZYME A; HYDROLASE; LOW DENSITY LIPOPROTEIN; MERCAPTAMINE; PANTETHEINASE; PANTOTHENIC ACID; UNCLASSIFIED DRUG; VANIN 1;

BIOLOGICAL ACTIVITY; CARDIOVASCULAR DISEASE; CELL MIGRATION; CHEMICAL STRUCTURE; ENZYME ACTIVITY; GENE LOCUS; HUMAN; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; SHORT SURVEY;

AMIDOHYDROLASES; AMINO ACID SEQUENCE; ANIMALS; CARDIOVASCULAR DISEASES; CELL MEMBRANE; COENZYME A; GPI-LINKED PROTEINS; HUMANS; INFLAMMATION; MICE; MOLECULAR SEQUENCE DATA; PANTETHEINE; PANTOTHENIC ACID;

EID: 84855833366     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.11.099     Document Type: Short Survey

References (51)

1. Martin F., Malergue F., Pitari G., et al. Vanin genes are clustered (human 6q22-24 and mouse 10A2B1) and encode isoforms of pantetheinase ectoenzymes. Immunogenetics 2001, 53:296-306.
2. Galland F., Malergue F., Bazin H., et al. Two human genes related to murine Vanin-1 are located on the long arm of human chromosome 6. Genomics 1998, 53:203-213.
3. Aurrand-Lions M., Galland F., Bazin H., et al. Vanin 1, a novel GPI-linked perivascular molecule involved in thymus homing. Immunity 1996, 5:391-405.
4. Maras B., Barra D., Dupre S., et al. Is pantetheinase the actual identity of mouse and human vanin-1 proteins?. Journal of Clinical Investigation 1999, 113:149-152.
5. Pitari G., Malergue F., Martin F., et al. Pantetheinase activity of membrane-bound Vanin-1: lack of free cysteamine in tissues of Vanin-1 deficient mice. FEBS Letters 2000, 483:149-154.
6. Nitto T., Inoue T., Node K. Alternative spliced variants in the pantetheinase family of genes expressed in human neutrophils. Gene 2008, 426:57-64.
7. Suzuki K., Watanabe T., Sakurai S., et al. A novel glycosylphosphatidylinositol-anchored protein on human leukocytes: a possible role for regulation of neutrophil adherence and migration. Journal of Immunology 1999, 162:4277-4284.
8. Udenfriend S., Kodukula K. How glycosyl-phosphatidylinositol-anchored membrane proteins are made. Annual Review of Biochemistry 1995, 64:563-591.
9. Koike S., Takeda Y., Hozumi Y., et al. Immunohistochemical localization in human tissues of GPI-80, a novel glycosylphosphatidyl inositol-anchored protein that may regulate neutrophil extravasation. Cell and Tissue Research 2002, 307:91-99.
10. Huang J., Takeda Y., Watanabe T., et al. A sandwich ELISA for detection of soluble GPI-80, a glycosylphosphatidyl-inositol (GPI)-anchored protein on human leukocytes involved in regulation of neutrophil adherence and migration - its release from activated neutrophils and presence in synovial fluid of rheumatoid arthritis patients. Microbiology and Immunology 2001, 45:467-471.
11. Wittwer C.T., Gahl W.A., Butler J.D., et al. Metabolism of pantethine in cystinosis. Journal of Clinical Investigation 1985, 76:1665-1672.
12. Jansen P., Kamsteeg M., Rodijk-Olthuis D., et al. Expression of the vanin gene family in normal and inflamed human skin: induction by proinflammatory cytokines. Journal of Investigative Dermatology 2009, 2167-2174.
13. Zhang B., Lo C., Shen L., et al. The role of vanin-1 and oxidative stress-related pathways in distinguishing acute and chronic pediatric ITP. Blood 2011.
14. Wittwer C.T., Burkhard D., Ririe K., et al. Purification and properties of a pantetheine-hydrolyzing enzyme from pig kidney. Journal of Biological Chemistry 1983, 258:9733-9738.
15. Martin F., Penet M.F., Malergue F., et al. Vanin-1(-/-) mice show decreased NSAID- and Schistosoma-induced intestinal inflammation associated with higher glutathione stores. Journal of Clinical Investigation 2004, 113:591-597.
16. Dupre S., Graziani M.T., Rosei M.A., et al. Enzymatic breakdown of pantethine to pantothenic acid and cystamine. European Journal of Biochemistry 1970, 16:571-578.
17. Wittwer C., Graves C., Peterson M., et al. Pantethine lipomodulation: evidence for cysteamine mediation in vitro and in vivo. Atherosclerosis 1987, 68:41-49.
18. Daugherty M., Polanuyer B., Farrell M., et al. Complete reconstitution of the human coenzyme a biosynthetic pathway via comparative genomics. Journal of Biological Chemistry 2002, 277:21431-21439.
19. Coloso R.M., Hirschberger L.L., Dominy J.E., et al. Cysteamine dioxygenase: evidence for the physiological conversion of cysteamine to hypotaurine in rat and mouse tissues. Taurine 6 2006, 25-36. Springer, USA. S.S. Oja, P. Saransaari (Eds.).
20. Butler J., Zetz M. Pantethine and cystamine deplete cystine from cystinotic fibroblasts via efflux of cysteamine-cysteine mixed disulfide. Journal of Clinical Investigation 1984, 74:411-416.
21. Wood P.L., Khan M.A., Moskal J.R. Cellular thiol pools are responsible for sequestration of cytotoxic reactive aldehydes: central role of free cysteine and cysteamine. Brain Research 2007, 1158:158-163.
22. Fox J.H., Barber D.S., Singh B., et al. Cystamine increases l-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation. Journal of Neurochemistry 2004, 91:413-422.
23. Jokay I., Kelemenics K., Gyuris A., et al. S-Methylthio-cysteine and cystamine are potent stimulators of thiol production and glutathione synthesis. Life Sciences 1997, 62:PL/27-PL/33.
24. Pinto J.T., Van Raamsdonk J.M., Leavitt B.R., et al. Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease. Journal of Neurochemistry 2005, 94:1087-1101.
25. Lesort M., Lee M., Tucholski J., et al. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. Journal of Biological Chemistry 2003, 278:3825-3830.
26. Hayes J.D., McLellan L.I. Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Radical Research 1999, 31:273-300.
27. Berruyer C., Martin F.M., Castellano R., et al. Vanin-1(-/-) mice exhibit a glutathione-mediated tissue resistance to oxidative stress. Molecular and Cellular Biology 2004, 24:7214-7224.
28. Berruyer C., Pouyet L., Millet V., et al. Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor gamma activity. Journal of Experimental Medicine 2006, 203:2817-2827.
29. Meghari S., Berruyer C., Lepidi H., et al. Vanin-1 controls granuloma formation and macrophage polarization in Coxiella burnetii infection. European Journal of Immunology 2007, 37:24-32.
30. Pouyet L., Roisin-Bouffay C., Cle ́ment A., et al. Epithelial vanin-1 controls inflammation-driven carcinogenesis in the colitis-associated colon cancer model. Inflammatory Bowel Diseases 2010, 16.
31. Roisin-Bouffay C., Castellano R., Valero R., et al. Mouse vanin-1 is cytoprotective for islet beta cells and regulates the development of type 1 diabetes. Diabetologia 2008, 51:1192-1201.
32. Ientile R., Campisi A., Raciti G., et al. Cystamine inhibits transglutaminase and caspase-3 cleavage in glutamate-exposed astroglial cells. Journal of Neuroscience Research 2003, 74:52-59.
33. Karpuj M., Becher M., Springer J., et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nature Medicine 2002, 8:143-149.
34. Greenberg C., Birckbichler P., Rice R. Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. FASEB Journal 1991, 5:3071-3077.
35. Di Leandro L., Maras B., Schinina M.E., et al. Cystamine restores GSTA3 levels in Vanin-1 null mice. Free Radical Biology and Medicine 2008, 44:1088-1096.
36. Jeon J., Lee H., Jang G., et al. Different inhibition characteristics of intracellular transglutaminase activity by cystamine and cysteamine. Experimental and Molecular Medicine 2004, 36:576-581.
37. Lorand L., Parameswaran K., Stenberg P., et al. Specificity of guinea pig liver transglutaminase for amine substrates. Biochemistry 1979, 18:1756-1765.
38. Bailey C.D.C., Johnson G.V.W. The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase. Neurobiology of Aging 2006, 27:871-879.
39. Yoshitake H., Takeda Y., Nitto T., et al. Cross-linking of GPI-80, a possible regulatory molecule of cell adhesion, induces up-regulation of CD11b/CD18 expression on neutrophil surfaces and shedding of L-selectin. Journal of Leukocyte Biology 2002, 71:205-211.
40. Huang J.-B., Takeda Y., Araki Y., et al. Molecular proximity of complement receptor type 3 (CR3) and the glycosylphosphatidylinositol-linked protein GPI-80 on neutrophils: effects of cell adherence, exogenous saccharides, and lipid raft disrupting agents. Molecular Immunology 2004, 40:1249-1256.
41. Nakamura-Sato Y., Sasaki K., Watanabe H., et al. Clustering on the forward surfaces of migrating neutrophils of a novel GPI-anchored protein that may regulate neutrophil adherence and migration. Journal of Leukocyte Biology 2000, 68:650-654.
42. Huang H., Dong X., Kang M.X., et al. Novel blood biomarkers of pancreatic cancer-associated diabetes mellitus identified by peripheral blood-based gene expression profiles. American Journal of Gastroenterology 2010, 105:1661-1669.
43. Min-Oo G., Fortin A., Pitari G., et al. Complex genetic control of susceptibility to malaria: positional cloning of the Char9 locus. Journal of Experimental Medicine 2007, 204:511-524.
44. Weimann B.I., Hermann D. Studies on wound healing: effects of calcium d-pantothenate on the migration, proliferation and protein synthesis of human dermal fibroblasts in culture. International Journal for Vitamin and Nutrition Research 1999, 69:113-119.
45. Goring H.H.H., Curran J.E., Johnson M.P., et al. Discovery of expression QTLs using large-scale transcriptional profiling in human lymphocytes. Nature Genetics 2007, 39:1208-1216.
46. Maggi G., Donati C., Criscuoli G. Pantethine: a physiological lipomodulating agent, in the treatment of hyperlipidemias. Current Therapeutic Research 1982, 32:380-386.
47. Bocos C., Herrera E. Pantethine stimulates lipolysis in adipose tissue and inhibits cholesterol and fatty acid synthesis in liver and intestinal mucosa in the normolipidemic rat. Environmental Toxicology and Pharmacology 1998, 6:59-66.
48. Cighetti G., Del Puppo M., Paroni R., et al. Pantethine inhibits cholesterol and fatty acid syntheses and stimulates carbon dioxide formation in isolated rat hepatocytes. Journal of Lipid Research 1987, 28:152-161.
49. Lombardini J., Militante J. Effects of taurine supplementation on cholesterol levels with potential ramification in atherosclerosis. Taurine 6 2006, 251-254. Springer, USA. S.S. Oja, P. Saransaari (Eds.).
50. Zhang M., Bi L.F., Fang J.H., et al. Beneficial effects of taurine on serum lipids in overweight or obese non-diabetic subjects. Amino Acids 2004, 26:267-271.
51. Yanagita T., Han S.-Y., Hu Y., et al. Taurine reduces the secretion of apolipoprotein B100 and lipids in HepG2 cells. Lipids in Health and Disease 2008, 7:38.